Medical Company Presents Promising New Hope For Parkinson's & Alzheimer's Patients

In the realm of neurodegenerative disease research, significant strides are being made. One such stride is the development of BioVie Inc.'s drug NE3107, which has shown promising preliminary results in treating both motor and non-motor symptoms for Parkinson's patients. The data is set to be presented at the International Conference on Alzheimer's and Parkinson's Diseases in 2024, a prestigious global event that brings together top researchers and clinicians from around the world. $BioVie(BIVI.US)$